Episode 10. Castleman Disease

In this episode, we talk Castleman Disease with Dr. Aaron Goodman (Papa Heme). We dissect the clinical and pathological classification, protean clinical manifestations, and approach to management in this rare lymphoproliferative disorder.

Show Notes

Excellent overview of Castleman Disease: https://ashpublications.org/blood/article/135/16/1353/452573/Overview-of-Castleman-disease

International consensus guideline for treatment of Idiopathic Multicentric Castleman Disease (iMCD): https://ashpublications.org/blood/article/132/20/2115/39506/International-evidence-based-consensus-treatment

Somatic alterations in Castleman Disease:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624446/
https://www.nature.com/articles/s41375-018-0323-6

Rituximab + Liposomal Doxorubicin in HHV8-positive MCD:
https://ashpublications.org/blood/article/124/24/3544/33494/Rituximab-plus-liposomal-doxorubicin-in-HIV

RCT on Siltuximab for MCD: https://pubmed.ncbi.nlm.nih.gov/25042199/

Long-term data on Siltuximab in MCD: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30257-1/fulltext

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk